Lasa Supergenerics quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1.2	20.0	−93.9%
EBITDA	−1.4	−0.5	—
EBITDA margin	−113.4%	−2.5%	−110.9 pts
Profit before tax	−3.5	−22.5	—
Net profit	−3.6	−21.1	—
EPS	−₹0.71	−₹4.22	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1.2	−0.1	2.2	3.1	20.0	39.1	33.1	39.4	30.8	22.8	26.7	24.3	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.1	0.0	0.0	0.0	0.1	2.4	0.1	1.9	0.0	0.0	0.0	0.1
	1.3	−0.1	2.2	3.1	20.1	41.5	33.2	41.3	30.8	22.8	26.7	24.4
	1.1	0.7	0.5	4.3	13.7	31.7	25.8	30.3	20.3	19.0	18.4	19.7
	0.7	−0.3	1.8	1.2	2.0	−3.4	−1.3	1.0	1.8	−0.6	1.5	−3.1
	0.2	0.0	0.2	0.8	1.2	1.4	1.5	1.6	1.6	1.5	1.6	1.6
	0.1	0.1	0.1	0.1	0.0	0.1	0.5	1.2	0.9	0.6	0.4	0.6
	1.6	1.3	1.6	1.6	1.6	3.9	2.8	2.8	2.8	2.7	2.7	2.7
	0.6	2.0	0.5	0.7	3.6	6.0	6.3	5.7	5.4	6.8	4.1	5.2
	4.3	3.9	4.6	8.7	22.1	39.7	35.6	42.7	32.7	30.0	28.7	26.5
	−1.4	−2.6	−0.7	−4.0	−0.5	3.4	0.8	0.8	1.8	−4.0	1.1	1.0
	−3.0	−3.9	−2.3	−5.6	−2.1	−0.5	−2.0	−2.0	−1.0	−6.6	−1.6	−1.6
Profit
	−3.0	−4.0	−2.4	−5.7	−2.0	1.8	−2.3	−1.3	−1.9	−7.2	−2.1	−2.1
	−0.5	0.0	0.0	0.0	−20.6	−23.9	8.2	0.0	0.0	−8.8	0.0	0.0
	−3.5	−4.0	−2.4	−5.7	−22.5	−22.1	5.9	−1.3	−1.9	−16.0	−2.1	−2.1
	0.1	0.2	0.1	0.6	−1.4	−7.8	0.4	1.9	0.9	−0.7	−0.6	−2.1
	0.1	0.2	0.1	0.6	−1.4	−7.8	0.4	1.9	0.9	−0.7	−0.6	−2.1
	−3.6	−4.2	−2.6	−6.3	−21.1	−14.3	5.5	−3.2	−2.7	−15.3	−1.5	−0.0
	−3.6	−4.2	−2.6	−6.3	−21.1	−14.3	5.5	−3.2	−2.7	−15.3	−1.5	−0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
	−3.6	−4.2	−2.6	−6.3	−21.1	−14.2	5.5	−3.2	−2.7	−15.2	−1.5	−0.0
Per share
	−₹0.71	−₹0.83	−₹0.51	−₹1.25	−₹4.22	−₹2.85	₹1.10	₹0.64	₹0.55	−₹3.05	−₹0.29	₹0.00
	−₹0.71	−₹0.83	−₹0.51	−₹1.25	−₹4.22	−₹2.85	₹1.10	₹0.64	₹0.55	−₹3.05	−₹0.29	₹0.00
Other comprehensive income — detail
	—	—	—	—	—	0.0	—	—	—	—	—	—
	—	—	—	—	—	0.0	—	—	—	—	—	—
Per share — as-filed variants
	−₹0.71	−₹0.83	−₹0.51	−₹1.25	−₹4.22	−₹2.85	₹1.10	₹0.64	₹0.55	−₹3.05	−₹0.29	₹0.00
	−₹0.71	−₹0.83	−₹0.51	−₹1.25	−₹4.22	−₹2.85	₹1.10	₹0.64	₹0.55	−₹3.05	−₹0.29	₹0.00
Regulatory disclosures — filed alongside, not part of the P&L
	—	0.4	—	0.3	—	1.2	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	−0.6	−0.5	−0.1	−2.5	4.3	10.8	8.6	8.1	8.8	4.3	6.7	7.8
	−49.5%	376.4%	−2.7%	−80.7%	21.6%	27.6%	25.9%	20.6%	28.4%	19.0%	25.3%	32.1%
Adjusted (ex-exceptional items) — derived
	−3.0	−4.0	−2.4	−5.7	−2.0	1.8	−2.3	−1.3	−1.9	−7.2	−2.1	−2.1
	−0.5	0.0	0.0	0.0	−20.6	−23.9	8.2	0.0	0.0	−8.8	0.0	0.0
	−3.1	−4.2	−2.6	−6.3	−1.8	1.2	−2.2	−3.2	−2.7	−6.9	−1.5	−0.0
	−₹0.62	−₹0.83	−₹0.51	−₹1.25	−₹0.37	₹0.23	−₹0.43	₹0.64	₹0.55	−₹1.37	−₹0.29	₹0.00

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMANGALAM BIOFILCHEM ORTINGLOBE VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹23.4 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	24.3	26.7	22.8	30.8	39.4	33.1	39.1	20.0	3.1	2.2	-0.1	1.2
Other Income	0.1	0.0	0.0	0.0	1.9	0.1	2.4	0.1	0.0	0.0	0.0	0.1
Total Income	24.4	26.7	22.8	30.8	41.3	33.2	41.5	20.1	3.1	2.2	-0.1	1.3
Expenses
+ Cost of Materials Consumed	19.7	18.4	19.0	20.3	30.3	25.8	31.7	13.7	4.3	0.5	0.7	1.1
+ Changes in Inventories	-3.1	1.5	-0.6	1.8	1.0	-1.3	-3.4	2.0	1.2	1.8	-0.3	0.7
+ Employee Benefit Expense	1.6	1.6	1.5	1.6	1.6	1.5	1.4	1.2	0.8	0.2	0.0	0.2
+ Finance Costs	0.6	0.4	0.6	0.9	1.2	0.5	0.1	0.0	0.1	0.1	0.1	0.1
+ Depreciation & Amortisation	2.7	2.7	2.7	2.8	2.8	2.8	3.9	1.6	1.6	1.6	1.3	1.6
+ Other Expenses	5.2	4.1	6.8	5.4	5.7	6.3	6.0	3.6	0.7	0.5	2.0	0.6
Total Expenses	26.5	28.7	30.0	32.7	42.7	35.6	39.7	22.1	8.7	4.6	3.9	4.3
EBITDA	1.0	1.1	-4.0	1.8	0.8	0.8	3.4	-0.5	-4.0	-0.7	-2.6	-1.4
EBIT	-1.6	-1.6	-6.6	-1.0	-2.0	-2.0	-0.5	-2.1	-5.6	-2.3	-3.9	-3.0
Profit
PBT before Exceptional Items	-2.1	-2.1	-7.2	-1.9	-1.3	-2.3	1.8	-2.0	-5.7	-2.4	-4.0	-3.0
+ Exceptional Items	0.0	0.0	-8.8	0.0	0.0	8.2	-23.9	-20.6	0.0	0.0	0.0	-0.5
Pretax Income	-2.1	-2.1	-16.0	-1.9	-1.3	5.9	-22.1	-22.5	-5.7	-2.4	-4.0	-3.5
+ Deferred Tax	-2.1	-0.6	-0.7	0.9	1.9	0.4	-7.8	-1.4	0.6	0.1	0.2	0.1
Tax Expense	-2.1	-0.6	-0.7	0.9	1.9	0.4	-7.8	-1.4	0.6	0.1	0.2	0.1
Net Income	-0.0	-1.5	-15.3	-2.7	-3.2	5.5	-14.3	-21.1	-6.3	-2.6	-4.2	-3.6
+ Net Income — Continuing Ops	-0.0	-1.5	-15.3	-2.7	-3.2	5.5	-14.3	-21.1	-6.3	-2.6	-4.2	-3.6
+ Other Comprehensive Income	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Comprehensive Income	-0.0	-1.5	-15.2	-2.7	-3.2	5.5	-14.2	-21.1	-6.3	-2.6	-4.2	-3.6
Per Share
Basic EPS	0.00	-0.29	-3.05	0.55	0.64	1.10	-2.85	-4.22	-1.25	-0.51	-0.83	-0.71
Diluted EPS	0.00	-0.29	-3.05	0.55	0.64	1.10	-2.85	-4.22	-1.25	-0.51	-0.83	-0.71
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.0	—	—	—	—	—
+ Items NOT to be Reclassified to P&L	—	—	—	—	—	—	0.0	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.00	-0.29	-3.05	0.55	0.64	1.10	-2.85	-4.22	-1.25	-0.51	-0.83	-0.71
Diluted EPS — Continuing Operations	0.00	-0.29	-3.05	0.55	0.64	1.10	-2.85	-4.22	-1.25	-0.51	-0.83	-0.71
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	1.2	—	0.3	—	0.4	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	7.8	6.7	4.3	8.8	8.1	8.6	10.8	4.3	-2.5	-0.1	-0.5	-0.6
Gross Margin %	32.07	25.25	19.02	28.43	20.60	25.89	27.63	21.60	-80.71	-2.73	376.43	-49.49
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-2.1	-2.1	-7.2	-1.9	-1.3	-2.3	1.8	-2.0	-5.7	-2.4	-4.0	-3.0
− Exceptional Items (reconciliation)	0.0	0.0	-8.8	0.0	0.0	8.2	-23.9	-20.6	0.0	0.0	0.0	-0.5
Net Income Adj (tax-effected)	-0.0	-1.5	-6.9	-2.7	-3.2	-2.2	1.2	-1.8	-6.3	-2.6	-4.2	-3.1
EPS Adj	0.00	-0.29	-1.37	0.55	0.64	-0.43	0.23	-0.37	-1.25	-0.51	-0.83	-0.62
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	50.1	50.1	50.1	50.1	50.1	50.1	50.1	50.1	50.1	50.1	50.1	50.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Lasa Supergenerics quarterly results

Lasa Supergenerics (NSE: LASA) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net loss was ₹3.6 crore, narrower than the loss of ₹21.1 crore in Q1 FY26 and narrower than the loss of ₹4.2 crore in Q4 FY26. Revenue from operations was ₹1.2 crore, down 93.9% year on year.

Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 14 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net loss: −₹3.6 Crloss ₹21.1 Cr in Q1 FY26loss ₹4.2 Cr in Q4 FY26
Q1 FY27 revenue: ₹1.2 Cr−93.9% vs Q1 FY26−₹13 lakh in Q4 FY26
Q2 FY26 net loss (a year earlier): −₹6.3 CrRevenue ₹3.1 Cr
Q1 FY27 EPS (basic): −₹0.71

Questions

When will Lasa Supergenerics announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 14 November 2025.

What will Lasa Supergenerics' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss was ₹6.3 crore and revenue from operations ₹3.1 crore. The latest quarter, Q1 FY27, had a net loss of ₹3.6 crore and revenue of ₹1.2 crore.

What was Lasa Supergenerics' net profit in FY26?

Consolidated net profit was a loss of ₹34.1 crore in FY26 (April 2025–March 2026), wider than the loss of ₹14.8 crore in FY25. It was a loss of ₹21.7 crore in FY24 and a loss of ₹38.6 crore in FY23.

What were Lasa Supergenerics' Q1 FY27 results?

Consolidated net loss was ₹3.6 crore, narrower than the loss of ₹21.1 crore in Q1 FY26 and narrower than the loss of ₹4.2 crore in Q4 FY26. Revenue from operations was ₹1.2 crore, down 93.9% year on year.

How has Lasa Supergenerics' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹6.3 crore in Q2 FY26, a loss of ₹2.6 crore in Q3 FY26, a loss of ₹4.2 crore in Q4 FY26 and a loss of ₹3.6 crore in Q1 FY27. That is a combined loss of ₹16.5 crore over the four quarters. Revenue from operations: ₹3.1 crore, ₹2.2 crore, ₹13 lakh and ₹1.2 crore.

What was Lasa Supergenerics' revenue in FY26?

Revenue from operations was ₹25.1 crore in FY26 (April 2025–March 2026), down 82.4% from ₹142 crore in FY25. It was ₹104 crore in FY24 and ₹130 crore in FY23: down 80.6% over three years, an average fall of 42.1% a year.

Where do these Lasa Supergenerics figures come from?

From Lasa Supergenerics' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.